title: [Effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus].
abstract: OBJECTIVE
  To evaluate the effect of sitagliptin in combination with metformin on glucose toxicity and lipotoxicity in patients with type 2 diabetes mellitus.
  
  
  METHODS
  . Eighty-two overweight and dyslipidemic patients (mean age 55.3 +/- 9.1 years) who had not achieved the goal levels of glycated hemoglobin (HbA1c) (mean level 8.3 +/- 1.6%) during metformin therapy and dietotherapy were examined. Group 1 patients received sitagliptin 100 mg/day in combination with metformin 2 g/day; Group 2 took metformin 1.5-2 g/day. The levels of fasting plasma glucose (FPG) levels, postprandial glycemia (PPG), HbA1c, body weight, body mass index, waist circumference, and waist-to-hip ratio, blood lipid composition, and the levels of insulin, leptin, adiponectin, HOMA-IR, and HOMA-beta were estimated at baseline and 6 months later. Visceral fat (VF) magnetic resonance imaging (MRI) was carried out.
  
  
  RESULTS
  Following 6 months, both groups showed positive changes in FPG, PPG, and HbA1c levels. HbA1c decreased from 8.3 +/- 1.6 to 6.6 +/- 1.24% in Group 1 and from 8.35 +/- 1.75 to 7.62 +/- 1.39% in Group 2. PPG and FPG reduced by an average of 2.67 and 3.3 mmol/l in Group 1 and by 2.1 and 1.8 mmol/l in Group 2. HOMA-beta increased by 23.4. conventional units (CU) in Group 1 and by 4.8 CU in Group 2. HOMA-IR was noted to display positive changes in both groups. The level of adiponectin rose by 1.9 ng/ml in Group 1 and by 0.49% ng/ml in Group 2 and that of leptin fell by 7.37 and 1.21 ng/ml, respectively. There were significant differences between the groups in anthropometric changes. MRI revealed a significant VF drop by 20.6 +/- 13.5 cm2 (7.5%) in Group 1 and by 5.7 +/- 3.75 cm2 (1.76%) in Group 2.
  
  
  CONCLUSIONS
  Combined therapy with sitagliptin and metformin caused reductions in glucose toxicity and lipotoxicity.
authors.forename: A S
authors.initials: AS
authors.lastname: Ametov
authors.forename: D G
authors.initials: DG
authors.lastname: Gusenbekova
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D050260:Carbohydrate Metabolism / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D050152:Intra-Abdominal Fat / Q000187:drug effects; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D008055:Lipids; D008687:Metformin; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D014230:Triazoles; C517652:hemoglobin A1c protein, human